Roivant Sciences, which is developing a range of drugs through various subsidiaries, has secured $1.1bn in a round led by the $93bn Vision Fund.
Vision Fund, the investment fund launched by telecommunications firm SoftBank, led a $1.1bn round for Switzerland-based drug developer Roivant Sciences today that also featured existing investors including pharmaceuticals distributor Dexxon.
Founded in 2014, Roivant pursues a business model whereby it develops therapeutics through a range of subsidiaries.
The subsidiaries in question include Myovant, which focuses on endocrine diseases and women’s health in general, Axovant (neurology), Dermavant (dermatology), Enzyvant (rare diseases) and Urovant (urology).
The funding will be used to launch…
